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Rapid identification of viruses is needed to monitor the blood supply for emerging threats. Here we present a method that meets 
these criteria and allows for the shotgun sequencing of novel, uncultured DNA viruses directly from human blood. This method 
employs selection based on the physical properties of viruses combined with sequence-independent amplification and cloning. We 
show that both single- and double-stranded DNA viruses can be recovered from blood samples using this approach. In addition, we 
report the discovery of novel anellovirus sequences in the blood of healthy donors. PCR primers designed to amplify these novel 
anellovirus sequences were then used to verify the presence of these viruses in the general donor population.
San Diego State University, San Diego, CA, USA
INTRODUCTION
New viral infections in humans 
may be emerging at an increasing rate 
(1). The safety of the blood supply 
is currently maintained by selective 
screening of donors (2), pathogen 
reduction (3), and nucleic acid and 
antibody testing for known viruses, 
including human immunodeficiency 
virus (HIV), hepatitis B virus (HBV), 
hepatitis C virus (HCV), human T cell 
lymphotrophic virus (HTLV), and West 
Nile virus (WNV). These practices 
have made the blood supply extremely 
safe from the transmission of known 
viruses (the risk of contracting HIV 
or HCV through a blood transfusion is 
less than 1 in 2,000,000) (4 ).
The largest potential threats to 
the blood supply are posed by novel 
pathogens, which would escape 
current screening techniques. In 
order to identify emerging viruses, 
an active surveillance system capable 
of continually monitoring the blood 
supply is needed. Hybridization to 
DNA microarrays containing all known 
viral sequences and low-stringency 
PCR using degenerate primers to 
highly conserved viral sequences have 
successfully been used to identify and 
characterize novel viruses (5,6). These 
methods rely on conserved sequences 
being present within viral genomes, 
which makes them inadequate for the 
discovery of completely novel viral 
types in human blood samples.
The use of representative differential 
amplification (RDA) (7) has led to the 
discovery of several novel viruses in 
humans, including HCV (8), hepatitis 
GB virus (9), herpesvirus 8 (10), and 
Torque teno virus (TTV) (11). RDA 
was originally intended for comparing 
two cellular genomes, and applying 
this method to viral discovery in human 
blood requires that the composition 
of the background host DNA to be 
subtracted out is similar in both the 
tester and driver samples. In addition, 
RDA typically involves large quantities 
of DNA, which would require a high 
level of viremia before the virus could 
be recovered. While RDA is appropriate 
if samples from the same individual 
are being compared before and after 
viral infection, it is not clear that this 
approach will be applicable to blood 
pooled from multiple individuals.
Two recent studies have presented 
viral discovery methods that utilize 
selection for viral particles (based on 
size, density, and nuclease resistance), 
followed by sequence-independent 
amplification (12,13). These approaches 
have been used to identify new bovine 
parvoviruses present in commercial 
bovine serum (12), sequence novel 
viruses from the plasma of patients 
with symptoms of acute viral infection 
(14), and diagnose herpes simplex virus 
type 1 (HSV-1) in the supernatant of 
infected cells isolated from the mouth-
washing material of a chronic fatigue 
syndrome patient (13).
Several viruses, such as TTV (15–
17), TTV-like mini virus (TLMV) (18), 
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SEN virus (SENV) (19), Epstein-Barr 
virus (20), and B19 (21) are found in the 
blood of healthy people. The process 
of discovering novel blood viruses is 
hindered by methodological limita-
tions such as low viral DNA content, 
abundance of host and mitochondrial 
DNA, and the absence of genes that are 
conserved among all viruses. Here we 
present a method to shotgun-sequence 
novel, uncultured DNA viruses directly 
from human blood. This method 
employs selection based on the physical 
properties of viruses combined with 
sequence-independent amplification 
and cloning. Using this method, we 
discovered novel anellovirus sequences 
in the blood of healthy donors.
MATERIALS AND METHODS
Blood Collection
All blood collection was performed 
by technicians at the General Clinical 
Research Center at the Scripps 
Research Institute (San Diego, CA, 
USA). Ten milliliters of blood were 
collected from healthy blood donors 
into sodium heparin vacutainers (BD 
Biosciences, Franklin Lakes, NJ, USA) 
and stored at 4°C until processing 
(within 1 week).
Sample Descriptions
Library 1 was constructed from 
blood pooled from 20 healthy donors 
collected in November 2004. Libraries 
2 and 3 were constructed from blood 
pooled from 15 healthy donors 
collected in February 2005. The pooled 
plasma samples for Libraries 1 and 2 
were spiked with 107 bacteriophage 
M13 particles per milliliter as a tracer to 
ensure the recovery of single-stranded 
DNA (ssDNA) viruses. Library 3 
was not spiked with any tracers. For 
screening with specific primers, plasma 
was pooled from approximately 100 
additional healthy donors (collected 
between September 2004 and February 
2005).
Isolation of Viral DNA
The methods for obtaining viral 
DNA from blood samples are outlined 
in Protocol 1. Whole blood samples 
were centrifuged at 3000× g at 4°C for 
10 min to pellet the blood cells. Eight 
and a half milliliters of cell-free plasma 
were loaded onto a cesium chloride 
(CsCl) step gradient consisting of 1 
mL each of 1.7, 1.5, and 1.2 g/mL in 
1× phosphate-buffered saline (1× PBS; 
137 mM NaCl, 2.7 mM KCl, 4.3 mM 
Na2HPO4, 1.4 mM KH2PO4, pH 7.3). 
The gradient was designed to capture 
all known groups of DNA viruses (22). 
The gradients were ultracentrifuged 
at 55,000× g at 4°C for 2 h, and the 
1.2–1.5 g/mL fraction was collected. 
This fraction was stained with SYBR® 
Gold (Molecular Probes, Eugene, 
OR, USA) and viewed under epifluo-
rescence and electron microscopy 
to ensure that it contained virus-like 
particles (23,24). The CsCl-purified 
viral particles were then incubated with 
0.2 volumes of chloroform for 10 min 
at room temperature. The chloroform 
was pelleted, and the supernatant was 
removed and incubated with 2.5 U 
DNase I (Sigma-Aldrich, St. Louis, 
MO, USA) per microliter of sample 
for 2 h at 37°C. This sample was then 
concentrated and washed twice with 
1× PBS on a Microcon® 30 (Millipore, 
Billerica, MA, USA). EDTA was added 
to a final concentration of 20 mM to 
inactivate the DNase I, and DNA was 
then extracted using the QIAamp® 
MinElute™ Virus Spin Kit (Qiagen, 
Valencia, CA, USA) according to the 
manufacturer’s instructions. Total DNA 
was also extracted from unprocessed 
cell-free plasma from the healthy 
donors using the QIAamp Blood Mini 
Kit (Qiagen). This was used for the 
comparison of human, mitochondrial, 
and TTV DNA found in unprocessed 
plasma versus viral DNA purified using 
the method outlined in Protocol 1.
PCR to Check DNA Quality
Viral DNA extracted from the blood 
samples was screened by PCR for the 
presence of (i) human 18S rDNA, (ii) 
human mitochondrial DNA, and (iii) 
TTV. All primer sequences are listed in 
Table 1. PCR products positive for TTV 
in the nested reaction were sequenced 
for verification. The PCR mixture (50 
μL total volume) for the specific primer 
Protocol 1. Overview of the Methodology for Obtaining Purified Viral DNA from 
Whole Blood Samples
1. Removal of blood cells by centrifugation
2. Purification of viral particles by CsCl density-dependent centrifugation
(results may be visualized by electron microscopy; see Figure 1)
3. Chloroform treatment
4. DNase I incubation
5. Concentration and desalting
6. DNA extraction
7. PCR for quality control (see Figure 2)
8. Sequence-independent amplification
9. DNA shearing
10. Linker-addition and PCR amplification of fragments
11. Cloning and sequencing
12. Bioinformatic analyses
13. Confirmation by specific PCR (see Figure 3)
Figure 1. Transmission electron micrographs 
of some viruses found in the blood of healthy 
donors.
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sets contained 5 μL of target DNA, 1× 
FideliTaq™ PCR Master Mix (USB, 
Cleveland, OH, USA), and 1 μM each 
primer. The thermal cycler conditions 
were 5 min at 94°C; 35 cycles of 1 min 
at 94°C, 1 min at 55°C, and 1 min at 
72°C; and 10 min at 72°C.
Electron Microscopy
The CsCl-purified viral particles 
were adsorbed to glow-discharged 
formvar-coated 200-mesh copper grids 
for 5 min. The grids were then stained 
in 1% uranyl acetate for 20 s and 
viewed using the FEI Tecnai 12 (FEI, 
Hillsboro, OR, USA). Digital images 
were recorded on a Tietz TemCam-
F214 camera (TVIPS, Gauting, 
Germany).
Recovery of Tracer Viruses
Adenovirus 7. To evaluate the 
recovery of known viruses using the 
methodology presented here, plasma 
samples from healthy human donors 
were spiked with 107 adenovirus 7 
particles per milliliter. The number of 
added viral particles was determined 
by direct epifluorescence counts of 
viruses (data not shown). The spiked 
samples were processed as outlined in 
Protocol 1. The presence of adenovirus 
7 was determined in both spiked and 
unspiked samples based on PCR for the 
hexon gene as previously described by 
Echavarria et al. (25). The PCR condi-
tions for the detection of the adenovirus 
7 sequence were identical to those 
described above. Adenovirus 7 was not 
used as a tracer in any of the samples 
used for constructing the shotgun 
libraries.
Bacteriophage M13. In order to 
determine the ability of this method 
to recover ssDNA viruses, the pooled 
plasma used to construct Libraries 1 
and 2 were spiked with 107 particles 
of bacteriophage M13 (22) per milli-
liter before processing the samples as 
outlined in Protocol 1. The presence 
of spiked M13 in the purified viral 
samples was not monitored by PCR, but 
was determined based on TBLASTX 
similarities of the shotgun library 
sequences.
Construction of Viral Shotgun 
Libraries
Linker-amplified shotgun 
libraries—Libraries 1 and 2. Once 
viral DNA samples were determined 
to be free of mitochondrial and host 
DNA, linker-amplified shotgun 
libraries (LASLs) were constructed 
by Lucigen (Middleton, WI, USA) 
using a modification of the protocol 
described by Breitbart et al. (www.
sci.sdsu.edu/PHAGE/LASL) (26). 
Total DNA was initially amplified 
using the strand-displacement 
enzyme Bst DNA polymerase 
(New England BioLabs, Beverly, 
MA, USA). The amplified DNA 
was then sheared into 1–2 kb 
fragments using a HydroShear® 
(GenMachines, San Carlos, CA, 
USA), the fragments were end-
repaired, and short double-stranded 
DNA (dsDNA) linkers were ligated 
to the ends. These fragments were 
then PCR-amplified using primers 
to the linkers and cloned into the 
pSMART vector as previously 
described (26). Transformants were 
sequenced by SymBio (Menlo Park, 
CA, USA) using the AmpL2 primer. 
Sequences have been submitted to 
GenBank® with the accession nos. 
DQ092578–DQ092599.
GenomiPhi and whole genome 
amplification—Library 3. For 
Library 3, an alternative method for 
constructing shotgun libraries was 
tested on the same sample that was 
used to make Library 2. The DNA 
was first amplified using the strand-
displacement φ29 DNA polymerase 
(GenomiPhi™; Amersham Biosciences, 
Piscataway, NJ, USA) according to the 
manufacturer’s protocol. The products 
of the GenomiPhi reaction were then 
fragmented and further amplified using 
the GenomePlex® Whole Genome 
Amplification Kit (Sigma-Aldrich). 
The resulting OmniPlex library was put 
through a PCR clean-up kit (Mo Bio 
Laboratories, Solana Beach, CA, USA) 
and cloned using pGEM® (Promega, 
Madison, WI, USA). Transformants 
were sequenced by the San Diego 
State University Microchemical Core 
Facility (San Diego, CA, USA) using 
the M13F primer.
Bioinformatic Analysis of Shotgun 
Library Sequences
Quality scores were assigned to the 
sequences using Phred (27,28), and 
the sequences were trimmed using 
Sequencher™ 4.0 (Gene Codes, Ann 
Arbor, MI, USA). Sequences were 
trimmed until there were not more 
than 3 bases with confidence scores 
below 25 within 25 bases of either 
end. Sequences were compared against 
GenBank using TBLASTX (29,30). 
For phylogenetic analyses of the novel 
anellovirus sequences (SDSU1 and 
SDSU2), sequences showing signif-
icant TBLASTX hits were downloaded 
from GenBank. The sequences were 
then aligned using CLUSTALX (31) 
and neighbor-joining trees were 
constructed, bootstrapped 1000 times, 
and analyzed using Treeview (see 
Figure 3) (32).
PCR for Specific Sequences 
Identified by Shotgun Library 
Sequencing
Primer 3 (33) was used to design 
primers to amplify three of the 
viral sequences identified through 
sequencing of the shotgun libraries. 
Figure 2. Control PCR assays to determine the qual-
ity of the purified viral DNA. A DNA sample was 
considered a good candidate for library construction if 
it was negative in the PCR for human 18S rDNA and 
mitochondria, and positive in the PCR for TTV. Purified 
viral DNA, viral DNA isolated from healthy donor plas-
ma using the method presented in Protocol 1; plasma, 
total DNA isolated from healthy donor plasma before 
any processing; +, DNA extracted from whole blood 
(18S and mitochondria reactions), DNA from a healthy 
donor plasma sample known to be positive for TTV, and 
DNA isolated from the glycerol stock of adenovirus 7, 
respectively; -, no target DNA added to PCR; spiked 
sample, purified viral DNA isolated from a plasma 
sample spiked with 107 adenovirus 7 particles per milli-
liter; unspiked sample, purified viral DNA isolated from 
the same plasma sample processed in parallel, but not 
spiked. TTV, Torque teno virus. 
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The primers were designed to amplify 
sequences that had top TBLASTX 
hits to an uncultured anellovirus 
(DQ092578), SENV (DQ092579), and 
TLMV (DQ092580).
The PCR mixture (50 μL total 
volume) for the specific primer sets 
contained 5 μL of target DNA, 1× 
FideliTaq PCR Master Mix, and 1 μM 
each primer. The thermal cycler condi-
tions were 5 min at 94°C; 35 cycles 
of 1 min at 94°C, 1 min at 60°–0.5°C 
per cycle, 1 min at 72°C; and 10 min 
at 72°C. The identity of PCR positives 
was confirmed by sequencing.
RESULTS
Electron Microscopy of Purified 
Blood Viruses
Electron microscopy (Figure 1) 
verified the presence of viral particles 
in the plasma of healthy blood donors. 
The majority of the viral particles 
observed were approximately 100 
nm in diameter. In all cases, the viral 
particles were concentrated in the band 
isolated from the CsCl gradient, and 
no viruses were observed in the other 
fractions after centrifugation (data not 
shown).
Removal of Human and 
Mitochondrial DNA
Because high host and mitochon-
drial DNA concentrations overwhelmed 
the viral DNA signal (data not shown), 
CsCl density-dependent centrifugation, 
chloroform, and DNase I treatments 
were used to remove human and 
mitochondrial DNA. Free human DNA 
was removed beyond the detection limit 
of the PCR assay by the CsCl centrifu-
gation and DNase I treatment (Figure 
2). The addition of chloroform was 
necessary to disrupt the mitochondrial 
membranes, making them susceptible 
to DNase I digestion. Viral nucleic 
acids were protected from DNase I 
degradation by the viral protein capsids, 
although some enveloped viruses may 
have been lost. PCR assays showed that 
this method significantly reduced the 
concentrations of host and mitochon-
drial DNA compared with whole 
plasma, without resulting in observable 
losses of viral DNA (Figure 2 and data 
not shown).
Recovery of Viral DNA
PCR-based control experiments 
showed that both naturally present 
TTV and artificially spiked adenovirus 
7 tracers were recovered from human 
plasma using this method (Figure 2). 
Because concentrations of adenovirus 
can reach up to 1010 viruses per milli-
liter in the blood of infected patients 
(34), an addition of 107 viruses per 
milliliter is physiologically relevant.
TBLASTX analysis of the sequences 
from the viral shotgun libraries showed 
that this method recovered artificially 
spiked bacteriophage M13 as well 
as naturally present anelloviruses. 
For the libraries that were artificially 
spiked with 107 bacteriophage M13 
particles per milliliter, 20%–40% of 
the shotgun library sequences origi-
nated from bacteriophage M13 (as 
determined by TBLASTX similarity). 
These sequences could be assembled 
into larger contigs, demonstrating 
that the genome of a virus present 
at a concentration of 107 virions 
Figure 3. Novel anellovirus sequences identified in the plasma of healthy donors. Sequences having 
top TBLASTX hits to small anellovirus 2 (DQ092578), SEN virus (DQ092579), and TLMV (DQ092580) 
were recovered from the shotgun libraries. (A) Specific PCR primers designed to amplify these novel 
anellovirus sequences verified the presence of these sequences in the plasma of different healthy do-
nors. (B–D) Phylogenetic trees showing the relationships of the anellovirus sequences identified in this 
study (SDSU1 and SDSU2) to previously sequenced anelloviruses. Sequences identified in this study are 
shown in red, SENV sequences are green, TTV sequences are blue, and the small anellovirus 2 sequence 
is light purple. All positive PCR products were sequenced for verification. The scale bar represents 0.1 
changes per 100 bp. TTV, Torque teno virus; TLMV, TTV-like mini virus; SENV, SEN virus. 
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per milliliter would be recovered at 
high coverage, and it is possible that 
complete genomes could be assembled 
using this method. Several naturally 
occurring sequences with similarity to 
known viruses were observed in each 
library (Table 2). In addition, approxi-
mately 10% of the shotgun sequences 
had no similarities in GenBank with 
an E-value <0.001. These sequences 
may represent undescribed groups of 
viruses.
Identification of Novel Viral 
Sequences
Sequences from the healthy donor 
plasma shotgun libraries with signif-
icant TBLASTX similarities to known 
viruses are listed in Table 2. Because 
numerous recent studies have demon-
strated the presence of anelloviruses in 
the blood of the general population, we 
further analyzed two of these sequences. 
Figure 3 shows the phylogenetic 
relationships of these novel sequences 
to previously sequenced anelloviruses. 
A 286-bp fragment recovered from 
Library 2 (SDSU1; DQ092578) was 
41% identical on the nucleotide level 
and 35% on the amino acid level to 
small anellovirus 2 (AY787831). 
A 284-bp sequence recovered from 
Library 3 (SDSU2; DQ092579) was 
67% identical on the nucleotide level 
and 63% identical on the amino acid 
level to SENV (AY206683) (Figure 3, 
C and D). These divergent anellovirus 
sequences constitute novel viruses 
identified using the methods presented 
here and contribute to the wide genomic 
heterogeneity of this group.
Specific PCR to Confirm the 
Presence of Novel Anelloviruses
PCR primers designed to amplify 
three of the novel anellovirus sequences 
identified in this study confirmed 
their presence in blood pooled from 
100 different healthy donors (Figure 
3A). PCR positives were sequenced 
for confirmation, and all amplified 
sequences were identical to those 
initially recovered from the shotgun 
libraries.
DISCUSSION
The method described here provides 
a new technique for sequencing novel 
DNA viruses from plasma samples. 
There is a high level of selection for 
viruses in this protocol 
through the removal of 
blood cells by centrifu-
gation, the purification of 
viruses by CsCl density-
dependent centrifugation, 
chloroform addition to 
lyse mitochondria, and 
DNase I treatment to 
remove nonviral DNA. 
This selection elimi-
nates the need for the 
background human 
DNA signal subtraction 
that is performed in 
RDA analysis (8). It is 
important to note that 
the method outlined here 
employs a CsCl gradient 
for purifying viruses 
instead of filtration-based 
techniques. Filtering 
samples through a 0.2-μm 
filter (12,13) to remove 
cells and mitochondria 
may result in the loss of 
large viral particles (e.g., 
some herpesviruses are 0.2 μm in 
diameter) (22).
Depletion of Human and 
Mitochondrial DNA
Removal of free human host DNA 
was a critical step in this method 
because free human DNA may be 
present at significantly higher concen-
trations than viral DNA in plasma. Free 
human DNA was removed beyond the 
detection limit of our PCR conditions 
for human 18S rDNA by the CsCl 
density-dependent centrifugation and 
DNase I treatment (Figure 2).
In addition to removing free DNA, 
it was also necessary to remove 
mitochondria from the plasma sample. 
Chiu et al. (35) have shown that 
mitochondrial DNA is present in human 
plasma in both particle-associated and 
free forms. Preliminary experiments 
showed that if the mitochondria were 
not specifically removed from the 
plasma sample (by chloroform and then 
DNase I treatment), all the sequences 
recovered from the shotgun libraries 
were mitochondrial in origin (data 
not shown). The depletion protocols 
described here efficiently reduced the 
concentrations of mitochondrial DNA 
Table 1. Primer Sequences Utilized in this Study
Primer Name Sequence Target Reference
18SF
18SR
5′-CCGCAGCTAGGAATAATGGAATAGGAC-3′
5′-GTTAGCATGCCAGAGTCTCGTTCGT-3′
Human 18S 
rDNA
Maxim Biotech  
(San Francisco, 
CA, USA)
Mit3130F
Mit3301R
5′-AGGACAAGAGAAATAAGGCC-3′
5′-TAAGAAGAGGAATTGAACCTCTGACTGTAA-3′
Human  
mitochondria (35)
TTVBF1
TTVBR1
TTVCF1
TTVCR1
5′-GTGGGACTTTCACTTGTCGGTGTC-3′
5′-GACAAATGGCAAGAAGATAAAGGCC-3′
5′-CAGACTCCGAGTTGCCATTGGAC-3′
5′-CACGTGTCGGGGCCTACTTCCG-3′
TTV
(outer PCR) (41)
TTVBF2
TTVBR2
TTVCF2
TTVCR2
5′-AGGTCACTAAGCACTCCGAGCG-3′
5′-GCGAAGTCTGGCCCCACTCAC-3′
5′-GCAACGAAAGTGAGTGGGGCCAG-3′
5′-GGTTTCCGCCGAGGATGACCT-3′
TTV
(inner PCR) (41)
hexAA1885F
hexAA1913R
5′-GCCGCAGTGGTCTTACATGCACATC-3′
5′-CAGCACGCCGCGGATGTCAAAGT-3′
Adenovi-
rus 7 (25)
AnelloF
AnelloR
5′-GCACATTCTTTTAAGAGCTGTTTTT-3′
5′-AGCAGACCCAGGACAACAAG-3′
Novel anel-
lovirus This study
SENF
SENR
5′-AAGGCAAAGGAAACATGGTG-3′
5′-TGTGAAGGGGCCTAGTGTTC-3′ Novel SENV This study
TLMVF
TLMVR
5′-CGAACCATATCCAACAGAACAA-3′
5′-GTGGTAATGATGGCATGCTG-3′ Novel TLMV This study
TTV, Torque teno virus; SENV, SEN virus; TLMV, TTV-like mini virus.
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to the point that we could no longer 
detect mitochondrial DNA by PCR 
(Figure 2), and only a few sequences 
with TBLASTX similarities to 
mitochondria were recovered from the 
shotgun libraries.
Identification of Novel Anellovirus 
Sequences
Among the shotgun sequences 
obtained from healthy donor plasma, 
several sequences with similarities to 
the anellovirus family were identified 
(Table 2). The anellovirus family 
(formerly part of the circovirus family) 
is a highly heterogeneous group of 
single-stranded, circular viruses, 
including TTV, TLMV, and SENV. 
Using the methodology presented 
here, we have detected several novel 
anellovirus sequences, which suggests 
that there is still undiscovered 
diversity within this family of viruses. 
Anelloviruses are present worldwide 
and are found in over 70% of the 
general population of Asia, Africa, 
and South America (17). These viruses 
appear to be less prevalent in the 
U.S. and Europe (16); however, TTV 
viremia occurs in 8%–42% of healthy 
blood donors in the U.S. (36,37) and 
47%–73% of individuals in European 
countries (17). It has been suggested 
that TTV and SENV are associated with 
posttransfusion hepatitis; however, no 
definitive links between the presence 
of these viruses and clinical pathology 
have been demonstrated.
Possible Loss of Enveloped Viruses
The chloroform treatment that is 
required for lysing mitochondria will 
also disrupt the membrane of enveloped 
viruses. In control experiments with the 
enveloped virus HSV-1, the protein 
capsid remained intact and protected 
the viral DNA from degradation even 
after removal of the envelope (data 
not shown). Therefore, at least some 
enveloped viruses can be recovered 
using this method. However, the capsid 
of some viruses may not be stable after 
the removal of the envelope, and if these 
viruses were rendered DNase-sensitive, 
then they would not be recovered using 
this approach. One possible alternative 
to the chloroform treatment is antibody-
based depletion of the mitochondria. 
However, we found that this method 
did not consistently reduce mitochon-
drial numbers and had variable effects 
on the efficiency of viral recovery (data 
not shown).
Blood Sample Collection and 
Storage
This method was tested on blood 
samples that were collected using 
heparin as the anticoagulant and stored 
at either room temperature or 4°C. 
One needs to take caution when using 
blood preserved in EDTA, acid citrate 
dextrose, sodium citrate, and potassium 
or ammonium oxalate because these 
compounds chelate cations that are 
required for effective DNase I digestion 
and may compromise the integrity of 
viral particles. Further studies need to 
be performed to determine the ability 
of this method to recover viruses 
from frozen samples, serum, or blood 
fraction paste.
Applications of this Protocol
Here we have shown that a method 
based on the selection for viral particles 
followed by sequence-independent 
amplification can recover DNA viral 
sequences from the blood of healthy 
people. Applying this technique to large 
donor pools will allow for the identi-
fication of viruses normally present 
in the blood supply. This will provide 
a baseline against which samples 
can be compared in order to identify 
emerging threats even before clinical 
symptoms are observed. In addition to 
its use for monitoring the blood supply, 
this method can also be applied to 
diagnose unknown viral infections in 
patients. For example, more than 50% 
of pneumonia cases and almost 60% 
of encephalitis cases requiring hospi-
talization in the U.S. have no known 
etiology (38,39). In the case of many 
viral infections, viremia phases are 
characterized by high viral titers, which 
would facilitate the sequencing of the 
viruses using this method. Knowledge 
Table 2. Sequences from the Healthy Blood Donor Shotgun Libraries with 
Significant TBLASTX Similarities to Known Viruses
Library 
(No.)
Top Known Virus Hit TBLASTX E-value
1
1
2
TTV-like mini virus
TTV-like mini virus
TTV-like mini virus
9e-04
3e-25
2e-15
1
1
1
1
Heliothis zea virus 1
Heliothis zea virus 1
Heliothis zea virus 1
Heliothis zea virus 1
1e-15
2e-16
9e-17
4e-11
1 Pseudorabies virus 7e-05
1 Bacteriophage φ3626 2e-27
1
1
Cowpox virus
Cowpox virus
1e-19
1e-19
1
1
Human endogenous retrovirus H (HERV-H)
Human endogenous retrovirus H (HERV-H)
1e-25
5e-25
1 Bacteriophage EJ-1 2e-05
1 Human herpesvirus 3 5e-05
1
1
TTV
TTV
2e-24
1e-04
2 Small anellovirus 2a 3e-06
1 Methanobacterium phage psiM2 1e-04
1 Spodoptera litura nucleopolyhedrovirus 7e-08
1 Chlamydia phage φCPAR39 1e-09
3 SEN virusa 8e-38
TTV, Torque teno virus.
aSequences that were further analyzed to identify phylogenetic relationships to known viruses 
(Figure 3, B–D).
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about the identity of these viruses may 
yield insights into treatment options.
Because many viruses are cell-
associated (e.g., Epstein-Barr virus 
and cytomegalovirus), one logical 
step for further development of this 
method is its application to human 
tissues. The method outlined here 
can also easily be adapted to identify 
RNA viruses through the addition of 
a reverse transcription step before the 
sequence-independent amplification 
(12,13). Finally, this method can also 
be applied to detect novel DNA viruses 
within animal populations, which is of 
potential importance for both farming 
and human health.
The protocol described here can 
be completed (sample collection 
to sequence data) in fewer than 2 
days, which is faster than traditional 
protocols that require obtaining the 
virus in culture. Once sequence data 
are obtained from the newly identified 
virus of interest, PCR primers can 
be designed to rapidly screen a 
large number of samples in order to 
determine the prevalence, abundance, 
and geographical distribution of the 
novel virus. The safety of the blood 
supply can be monitored, and viral 
sequences can be compared in order to 
determine the origin of the virus and 
epidemiological links between patients 
(40).
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